Status:
COMPLETED
Carbetocin at Elective Cesarean Delivery Part 4
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Conditions:
Postpartum Hemorrhage
Eligibility:
FEMALE
18-50 years
Phase:
NA
Brief Summary
PostPartum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the most commonly used uterotonic drug to prevent and treat PPH in North America. However oxytocin has a very shor...
Detailed Description
The current oxytocin regimen requires the administration of a continuous infusion to achieve sustained uterotonic activity, which can be associated with a number of side effects and unpredictable effi...
Eligibility Criteria
Inclusion
- Elective cesarean delivery under spinal anesthesia.
- Written informed consent to participate in this study.
- Term pregnancy
Exclusion
- Refusal to give written informed consent.
- Allergy or hypersensitivity to carbetocin or oxytocin.
- Conditions that predispose to uterine atony and postpartum hemorrhage, such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis.
- Hepatic, renal, and vascular disease.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT02264769
Start Date
October 1 2014
End Date
May 1 2015
Last Update
May 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G1X5